News
- Author:
- Ted Bosworth
Publish date: October 2, 2019
MADRID – Prespecified analysis of newly published TRIMARIN/TRIGGER trials might guide clinical choices.
News
- Author:
- Ted Bosworth
Publish date: October 2, 2019
MADRID – Pirfenidone inhibits progression of unclassifiable interstitial lung disease in placebo-controlled trial.
News
- Author:
- Ted Bosworth
Publish date: September 30, 2019
MADRID – The trial, called INBUILD, enrolled patients who had progressive lung diseas...
News
- Author:
- Ted Bosworth
Publish date: September 12, 2019
NEW YORK – Increasing options for hidradenitis suppurativa might be particularly relevant to black patients.
News
- Author:
- Ted Bosworth
Publish date: September 9, 2019
NEW YORK – Because of the slow reversal of postinflammatory hyperpigmentation, it is imperative in skin of color patients to employ therapies with ...
News
- Author:
- Ted Bosworth
Publish date: August 23, 2019
NEW YORK – Elimination of resident-memory T cells is showing promise for durable vitiligo control.
News
- Author:
- Ted Bosworth
Publish date: August 22, 2019
NEW YORK – Dermatologists do not reliably address preventable risks of biologics and glucocorticoids.
News
- Author:
- Ted Bosworth
Publish date: August 14, 2019
Elevated blood pressure in midlife is associated with risk of subsequent dementia, but whether the risk is treatable is unclear.
News
- Author:
- Ted Bosworth
Publish date: August 14, 2019
Ankylosing spondylitis by modified New York criteria and radiographic axial spondyloarthritis by Assessment of SpondyloArthritis international Soci...
News
- Author:
- Ted Bosworth
Publish date: August 13, 2019
NEW YORK – Nicotinamide products are being examined in more than 90 active and recruiting trials listed on clinicaltrials.gov.
News
- Author:
- Ted Bosworth
Publish date: August 13, 2019
NEW YORK – Dermatologists not now offering cosmetic botulinum toxin injections are encouraged to start.
News
- Author:
- Ted Bosworth
Publish date: August 8, 2019
NEW YORK – A growing list of skin cancer chemopreventive agents is expanding options for risk management.
News
- Author:
- Ted Bosworth
Publish date: July 28, 2019
NEW YORK – Even in a private office setting, failure to engage a trained translator is discouraged.
News
- Author:
- Ted Bosworth
Publish date: July 26, 2019
NEW YORK – Even for persistent allergic dermatitis linked to a prosthetic device, explantation might not be helpful.
News
- Author:
- Ted Bosworth
Publish date: July 20, 2019
MADRID – After stopping a prior TNF inhibitor, there was no advantage to switching to the anti–IL-17 biologic secukinumab over a different TNFi .
